Looking to sell Benchling stock or options?
Contact usBenchling is a developer of a laboratory collaboration platform that aims to expedite and enhance teamwork in life science research. Benchling's platform offers a range of integrated applications that are designed to speed up R&D processes at all stages. This enables scientists to design, share, and document experiments, and share DNA-sequence data via the cloud. As a result, researchers have the necessary resources to speed up, assess, and predict R&D from discovery to bioprocessing, all from a single platform.
Draper Associates, Tiger Global Management, Rogue Capital, ICONIQ Growth, Rock Health Capital, Elad Gil, Y Combinator, Lone Pine Capital, Ashton Kutcher, Artisanal Ventures, Lux Capital, Spark Capital, Benchmark Capital Holdings, Matt Huang, Christopher Golda, Michael Montano, Thrive Capital, Adam Draper, Eight Roads, F-Prime Capital, Foreword, Ensemble Labs, Menlo Ventures, Balaji Srinivasan, Byers Capital.
Benchling is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Benchling stock. Depending on Benchling’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Benchling stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Benchling stock in two ways. First, Benchling employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Benchling stock. Note that all transactions in Benchling shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Benchling stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Benchling stock. Typically, shares of private companies like Benchling are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Nov 2021, Benchling is reported to have closed an equity financing in which the investors valued the company at $6.1B. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Benchling shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Benchling is not currently publicly traded, it does not have a ticker symbol.
Benchling has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Benchling is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Benchling shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
The partnership enables Sanofi to fast-track pharmaceutical processes by updating legacy software.
Benchling announced that Zealand Pharma A/S, a biotechnology company focused on the discovery and development of peptide-based medicines, has selected the Benchling R&D Cloud as its central source of truth for scientific data.
Benchling Bioprocess delivers new design, planning, and execution capabilities on a unified platform, to address the evolving requirements of modern process development SAN FRANCISCO, Sept. 19, 2023 /PRNewswire/ -- Benchling announced Benchling Bioprocess, a …
New product features include JMP integration, BLAST, and AlphaFold to drive faster decision-making and better data-driven insights as labs scale their R&D SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- Benchling, the R&D Cloud powering the biotechnology industry…
Benchling partners with Allotrope, backing industry standards and making library of open source industry data converters freely available to the scientific community SAN FRANCISCO, May 16, 2023 /PRNewswire/ -- Benchling, the R&D Cloud powering the biotechnolo…
The startup joins a growing number of U.S. firms, including Facebook-parent Meta Platforms Inc, Amazon.com Inc and several startups, to downsize its workforce
Rigorous examination confirms Benchling offers best-in-class security to protect its global biotech customer base SAN FRANCISCO, Jan. 26, 2023 /PRNewswire/ -- Benchling, the R&D Cloud powering the biotechnology industry, announced it has successfully complete…
Benchling, the R&D Cloud powering the biotechnology industry, announced the appointment of new executive leadership to its engineering and field organizations. These hires come at the same time the company achieved significant financial milestones. In the first half of its fiscal year, Benchling surpassed 1,000 customers and increased subscription revenue 90% year-over-year. Dollar-based net expansion was greater than 150%, indicative of customers rapidly growing their use of the R&D Cloud.